18 May 2024
On 18 May 2024, the People’s Government of Shenzhen Municipality issued the “Implementation Measures for Further Increasing the Attraction and Utilization of Foreign Investment” (“the Measures”). The Measures proposed to encourage foreign-invested enterprises to legally conduct clinical trials of overseas-listed cell and gene therapy drugs in Shenzhen Municipality, establish an international clinical trial centre in the Guangdong-Hong Kong-Macao Greater Bay Area and faciliate the approval and application of clinically urgent medicines and medical devices that are under the category of “Hong Kong-Macao Medicines and Devices” in designated medical institutions of Shenzhen Municipality. In addition, the Measures proposed to leverage the role of National Medical Products Administration sub-center in the Greater Bay Area in terms of drug review, approval and inspection and provide registration services for drugs from Hong Kong and Macau. The Measures will be effective from 1 June 2024 and will be valid for 5 years.